Xiaonan Zhang
- E-post:
- xiaonan.zhang@igp.uu.se
- Besöksadress:
- Dag Hammarskjölds väg 20
751 37 Uppsala - Postadress:
- Rudbecklaboratoriet
751 85 Uppsala
Mer information visas för dig som medarbetare om du loggar in.
Biografi
RESEARCH EXPERIENCES
2020.02 – Present, Researcher/Project leader in Department of Immunology, Genetics and Pathology, Uppsala University. Main research focus: Finding and understanding mutations that cause cancer and pursue novel cancer therapeutic strategies by targeting cancer-specific vulnerabilities in cell-cycle inactive cancer cell populations.
2019.01 – 2020.02, Visiting researcher in Department of Obstetrics, Gynaecology and Women's Health, University of Minnesota, USA. Main research focus: Targeting metabolism variations in ovarian carcinoma in metabolically compromised 3D microenvironments.
2015.08 – 2019.01, Post-doctoral fellow at Karolinska Institute, Sweden / Linkoping University, Sweden. Main research focus: Developing efficient strategies for cancer treatments by modulating redox pathways in tumour.
CURRENT FUNDING
2023-2025, Swedish Childhood Cancer Project Fund.
2023-2024, Lena Wäppling's Fund.
2022-2025, Göran Gustafssons Stiftelse's large prize fund on Medicine, Sweden.
2022-2024, Jeanssons Stiftelse Grant, Sweden.
2021-2025, Research position (Forskarassistent) with 4-year research funding, Swedish Childhood Cancer Fund.
PAST FUNDING
Swedish Childhood Cancer Fund.
Robert Lundbergs Fund.
EDUCATIONAL BACKGROUND
2011-2015, Ph.D at Department of Oncology-Pathology / Cancer Centre Karolinska, Karolinska Institute, Sweden.
2008-2010, M.Sc in Biomedicine, Chalmers University of Technology, Gothenburg, Sweden
TEACHING PORTFOLIO
Course leader in Master programme of Forensic Medicine, Uppsala University, Sweden
Forskning
My research focuses on exploring the unique features of quiescent tumor cells that are resistant to conventional anticancer treatments, specifically the mitochondria. By studying these features, I hope to develop more effective therapeutic strategies for clinical treatment
Specific topics I am working with:
1. The mutations in mitochondria affect the quiescent cell populations in solid tumours (CRC and neuroblastoma) during tumorigenesis.
2. Drug screening to identify novel chemicals target MYCN-amplificated neuroblastoma in 3D based tumour model, targets of the novel drug candidate, MYCN independence.
3. Identification and confirmation of novel targets under LOH process in CRC and Neuroblastoma, autophagy reaction under certain mitochondrial inhibition, the vulnerabilities related to autophagy for the treatment of neuroblastoma.
Here is my main Publication list.
Publikationer
Urval av publikationer
- Iron Chelator VLX600 Inhibits Mitochondrial Respiration and Promotes Sensitization of Neuroblastoma Cells in Nutrition-Restricted Conditions (2022)
- Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity (2022)
- Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries (2021)
- Targeting Loss of Heterozygosity (2021)
- Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570 (2020)
- Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers (2020)
Senaste publikationer
- Quiescent Cancer Cells (2023)
- Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells (2023)
- Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways (2023)
- Genetic differences between primary and metastatic cancer (2023)
- Iron Chelator VLX600 Inhibits Mitochondrial Respiration and Promotes Sensitization of Neuroblastoma Cells in Nutrition-Restricted Conditions (2022)
Alla publikationer
Artiklar
- Quiescent Cancer Cells (2023)
- Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells (2023)
- Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways (2023)
- Genetic differences between primary and metastatic cancer (2023)
- Iron Chelator VLX600 Inhibits Mitochondrial Respiration and Promotes Sensitization of Neuroblastoma Cells in Nutrition-Restricted Conditions (2022)
- Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity (2022)
- Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries (2021)
- Targeting Loss of Heterozygosity (2021)
- Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570 (2020)
- Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers (2020)